Adlai Nortye
Adlai Nortye engages in research and development of biopharmaceuticals for cancer immunotherapy.
Launch date
Employees
Market cap
AUD131m
Enterprise valuation
AUD40m (Public information from Sep 2024)
Share price
$2.1 ANL
Hangzhou Zhejiang (HQ)
Financials
Estimates*
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 45.7m | - | 5.0m | - | 255m | 55.7m |
| % growth | - | - | - | - | - | (78 %) |
| EBITDA | (54.3m) | (57.3m) | (101m) | - | - | - |
| % EBITDA margin | (119 %) | - | (2024 %) | - | - | - |
| Profit | (56.7m) | (58.8m) | (105m) | - | - | - |
| % profit margin | (124 %) | - | (2097 %) | - | - | - |
| EV / revenue | - | - | 66.3x | - | 0.4x | 1.9x |
| EV / EBITDA | - | - | -3.3x | - | - | - |
| R&D budget | 42.1m | 54.5m | 58.2m | - | - | - |
| R&D % of revenue | 92 % | - | 1163 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | Series A | |
$53.0m | Series B | ||
| N/A | $100m | Series C | |
$100m | Series D | ||
* | N/A | $57.5m | IPO |
* | N/A | $40.0m | Private Placement VC |
| Total Funding | AUD453m | ||
Related Content
Recent News about Adlai Nortye
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.